Stopped
LY3541860 · Relapsing Multiple Sclerosis
Trial terminated
Eli Lilly and CompanyPhase 2 NCT06220669 Registry history of NCT06220669 on ClinicalTrials.gov (opens the registry)
52 trials changed in the last 30 days: 1 stopped, 21 with notable changes, 30 with minor changes only.
Trial terminated
Eli Lilly and CompanyPhase 2 NCT06220669 Registry history of NCT06220669 on ClinicalTrials.gov (opens the registry)
Primary and study completion pushed from Jan 2028 to Oct 2028
Also in this update: Enrollment reduced: 127 → 90 participants
Eli Lilly and CompanyPhase 1 NCT06809400 Registry history of NCT06809400 on ClinicalTrials.gov (opens the registry)
Primary completion pushed from Apr 2027 to Sep 2028
Eli Lilly and CompanyPhase 1 NCT07226843 Registry history of NCT07226843 on ClinicalTrials.gov (opens the registry)
Primary endpoint(s) modified
Also in this update: Results posted: Oct 16, 2026; Trial completed
Eli Lilly and CompanyPhase 3 NCT06280716 Registry history of NCT06280716 on ClinicalTrials.gov (opens the registry)
Primary endpoint(s) modified
Also in this update: Interventions modified; Trial arms changed: 3 → 4
Eli Lilly and CompanyPhase 1 NCT06465069 Registry history of NCT06465069 on ClinicalTrials.gov (opens the registry)
Primary endpoint(s) modified
Also in this update: Phase changed: Phase 1/2 → Phase 3; Sponsor changed: Akouos, Inc. to Eli Lilly and Company
Eli Lilly and CompanyPhase 3 NCT05821959 Registry history of NCT05821959 on ClinicalTrials.gov (opens the registry)
Recruitment opened
Also in this update: Start date changed from estimate of Sep 2026 to Jul 8, 2026
Eli Lilly and CompanyPhase 3 NCT07668336 Registry history of NCT07668336 on ClinicalTrials.gov (opens the registry)
Recruitment opened
Eli Lilly and CompanyPhase 3 NCT07817875 Registry history of NCT07817875 on ClinicalTrials.gov (opens the registry)
Recruitment opened
Eli Lilly and CompanyPhase 3 NCT07775300 Registry history of NCT07775300 on ClinicalTrials.gov (opens the registry)
Recruitment opened
Also in this update: Start date changed from estimate of Sep 2026 to Aug 26, 2026
Eli Lilly and CompanyPhase 3 NCT07794579 Registry history of NCT07794579 on ClinicalTrials.gov (opens the registry)
Recruitment opened
Eli Lilly and CompanyPhase 1 NCT07801300 Registry history of NCT07801300 on ClinicalTrials.gov (opens the registry)
Recruitment opened
Eli Lilly and CompanyPhase 1 NCT07808060 Registry history of NCT07808060 on ClinicalTrials.gov (opens the registry)
Recruitment opened
Eli Lilly and CompanyPhase 1 NCT07808073 Registry history of NCT07808073 on ClinicalTrials.gov (opens the registry)
Recruitment opened
And 1 more change in the last 30 days
Eli Lilly and CompanyPhase 1 NCT07787169 Registry history of NCT07787169 on ClinicalTrials.gov (opens the registry)
Recruitment opened
Eli Lilly and CompanyPhase 2 NCT07759245 Registry history of NCT07759245 on ClinicalTrials.gov (opens the registry)
Recruitment opened
Eli Lilly and CompanyPhase 2 NCT07783802 Registry history of NCT07783802 on ClinicalTrials.gov (opens the registry)
Recruitment opened
Eli Lilly and CompanyPhase 1 NCT07803744 Registry history of NCT07803744 on ClinicalTrials.gov (opens the registry)
Recruitment opened
Eli Lilly and CompanyPhase 1 NCT07818967 Registry history of NCT07818967 on ClinicalTrials.gov (opens the registry)
Recruitment opened
Eli Lilly and CompanyPhase 1 NCT07765498 Registry history of NCT07765498 on ClinicalTrials.gov (opens the registry)
Recruitment opened
Eli Lilly and CompanyPhase 1 NCT07794592 Registry history of NCT07794592 on ClinicalTrials.gov (opens the registry)
Trial completed
Also in this update: Study completion date changed from estimate of Dec 2026 to Sep 9, 2026
Eli Lilly and CompanyPhase 2 NCT02747004 Registry history of NCT02747004 on ClinicalTrials.gov (opens the registry)
Trial completed
Morphic Therapeutic, Inc. (A Wholly Owned Subsidiary of Eli Lilly and Company)Phase 2 NCT05611671 Registry history of NCT05611671 on ClinicalTrials.gov (opens the registry)
Trial completed
Eli Lilly and CompanyPhase 4 NCT07006792 Registry history of NCT07006792 on ClinicalTrials.gov (opens the registry)
Trial completed
Eli Lilly and CompanyPhase 1 NCT07662798 Registry history of NCT07662798 on ClinicalTrials.gov (opens the registry)
Enrollment closed, study ongoing
Also in this update: Primary completion date changed from estimate of Dec 2026 to Apr 2, 2025
Eli Lilly and CompanyPhase 1 NCT05307705 Registry history of NCT05307705 on ClinicalTrials.gov (opens the registry)
Enrollment closed, study ongoing
Eli Lilly and CompanyPhase 2 NCT07215559 Registry history of NCT07215559 on ClinicalTrials.gov (opens the registry)
Enrollment closed, study ongoing
Eli Lilly and CompanyPhase 3 NCT07153471 Registry history of NCT07153471 on ClinicalTrials.gov (opens the registry)
Enrollment closed, study ongoing
And 2 more changes in the last 30 days
Eli Lilly and CompanyPhase 2 NCT06598943 Registry history of NCT06598943 on ClinicalTrials.gov (opens the registry)
Enrollment closed, study ongoing
Eli Lilly and CompanyPhase 1 NCT07707375 Registry history of NCT07707375 on ClinicalTrials.gov (opens the registry)
Trial completed
Eli Lilly and CompanyPhase 2 NCT06603571 Registry history of NCT06603571 on ClinicalTrials.gov (opens the registry)
Enrollment closed, study ongoing
Also in this update: Primary and study completion moved earlier from Nov 2027 to Aug 2027
Eli Lilly and CompanyPhase 4 NCT06864026 Registry history of NCT06864026 on ClinicalTrials.gov (opens the registry)
Primary and study completion pushed from Jul 2030 to Sep 2030
Also in this update: Trial sites expanded: 9 → 12 locations; Start date pushed from Oct 2026 to Nov 2026
Eli Lilly and CompanyPhase 4 NCT07838155 Registry history of NCT07838155 on ClinicalTrials.gov (opens the registry)
Trial completed
Eli Lilly and CompanyPhase 1 NCT06280703 Registry history of NCT06280703 on ClinicalTrials.gov (opens the registry)
Trial completed
Eli Lilly and CompanyPhase 1 NCT07545590 Registry history of NCT07545590 on ClinicalTrials.gov (opens the registry)
Enrollment closed, study ongoing
Eli Lilly and CompanyPhase 1 NCT07701083 Registry history of NCT07701083 on ClinicalTrials.gov (opens the registry)
Trial completed
Eli Lilly and CompanyPhase 1 NCT07346495 Registry history of NCT07346495 on ClinicalTrials.gov (opens the registry)
Trial completed
Also in this update: Final enrollment: 200 participants (planned 225)
Eli Lilly and CompanyPhase 1 NCT06148272 Registry history of NCT06148272 on ClinicalTrials.gov (opens the registry)
Primary and study completion pushed from Jul 2026 to Nov 2026
Eli Lilly and CompanyPhase 1 NCT06606106 Registry history of NCT06606106 on ClinicalTrials.gov (opens the registry)
Primary and study completion pushed from Aug 2026 to Nov 2026
Eli Lilly and CompanyPhase 1 NCT07165002 Registry history of NCT07165002 on ClinicalTrials.gov (opens the registry)
Primary and study completion pushed from Dec 2026 to Mar 2027
Eli Lilly and CompanyPhase 1 NCT06945406 Registry history of NCT06945406 on ClinicalTrials.gov (opens the registry)
Trial sites expanded: 0 → 18 locations
Eli Lilly and CompanyPhase 2 NCT07814417 Registry history of NCT07814417 on ClinicalTrials.gov (opens the registry)
Trial sites reduced: 136 → 131 locations
Eli Lilly and CompanyPhase 3 NCT07222332 Registry history of NCT07222332 on ClinicalTrials.gov (opens the registry)
Trial sites reduced: 148 → 143 locations
And 1 more change in the last 30 days
Eli Lilly and CompanyPhase 3 NCT07282600 Registry history of NCT07282600 on ClinicalTrials.gov (opens the registry)
Trial sites reduced: 284 → 276 locations
And 1 more change in the last 30 days
Eli Lilly and CompanyPhase 3 NCT07218380 Registry history of NCT07218380 on ClinicalTrials.gov (opens the registry)
Trial sites expanded: 3 → 10 locations
And 1 more change in the last 30 days
Eli Lilly and CompanyPhase 4 NCT07822880 Registry history of NCT07822880 on ClinicalTrials.gov (opens the registry)
Trial sites expanded: 161 → 170 locations
Eli Lilly and CompanyPhase 3 NCT07223593 Registry history of NCT07223593 on ClinicalTrials.gov (opens the registry)
Trial sites reduced: 162 → 158 locations
Eli Lilly and CompanyPhase 3 NCT07321886 Registry history of NCT07321886 on ClinicalTrials.gov (opens the registry)
Trial sites expanded: 11 → 15 locations
Eli Lilly and CompanyPhase 1 NCT07598370 Registry history of NCT07598370 on ClinicalTrials.gov (opens the registry)
Trial sites expanded: 10 → 16 locations
Eli Lilly and CompanyPhase 1 NCT07787182 Registry history of NCT07787182 on ClinicalTrials.gov (opens the registry)
Study completion moved earlier from May 2029 to Feb 2029
Also in this update: Primary completion moved earlier from May 2028 to Feb 2028
Eli Lilly and CompanyPhase 1/2 NCT06721013 Registry history of NCT06721013 on ClinicalTrials.gov (opens the registry)
| First posted | Trial | Phase | Status |
|---|---|---|---|
| 2026-10-19 | NCT07881432 A Study of EloraTZP in Adult Participants With Obesity Without Type 2 Diabetes | Phase 3 | Not Yet Recruiting |
| 2026-10-19 | NCT07881458 A Study of EloraTZP in Adult Participants With Obesity or Overweight and Type 2 Diabetes | Phase 3 | Not Yet Recruiting |
| 2026-10-09 | NCT07867327 A Study of LY4515100 in Healthy Male Participants | Phase 1 | Not Yet Recruiting |
| 2026-10-09 | NCT07867340 A Study of Single and Multiple Doses of LY5625573 in Healthy Participants, Including… | Phase 1 | Not Yet Recruiting |
| 2026-09-28 | NCT07843459 A Study of LY4560736 in Healthy Participants and Participants With Alzheimer's Disease… | Phase 1 | Not Yet Recruiting |
| 2026-09-24 | NCT07838155 A Study of Donanemab (LY3002813) in Participants With Early Symptomatic Alzheimer's… | Phase 4 | Not Yet Recruiting |
| Phase 1 | 69 | |
| Phase 1/2 | 5 | |
| Phase 2 | 42 | |
| Phase 2/3 | 1 | |
| Phase 3 | 93 | |
| Phase 4 | 11 |
Obesity (52) · Diabetes (26) · Breast Cancer (24) · Alzheimer's Disease (19) · Dementia (19) · Lung Cancer (19) · Non-Small Cell Lung Cancer (NSCLC) (19) · Type 2 Diabetes (19) · Colorectal Cancer (10) · Head & Neck Cancer (8)